Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...

Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Aldosterone is a hormone that helps regulate sodium and potassium levels in the blood. Hyperaldosteronism and hypoaldosteronism are conditions involving abnormal aldosterone levels. The adrenal glands ...

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...

Mineralys Therapeutics, Inc. has announced the publication of detailed results from its pivotal Phase 2 Advance-HTN trial in the New England Journal of Medicine. The study assessed lorundrostat, an ...